IP Library Granted Patent US 8,652,793
Granted Patent B2
US 8,652,793 · App. 13/455,979 · Granted Feb 18, 2014

Solid phase-bound elastase-binding assay for the measurement of alpha

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,652,793
App. No.
13/455,979
Granted
Feb 18, 2014
Kind
B2
Abstract

The present invention relates to a method for the measurement of active alpha 1 -proteinase inhibitor (A1PI) in a sample, comprising the steps of binding elastase to a solid support, letting the A1PI contained in the sample bind to the solid phase-bound elastase, and detecting solid phase-bound A1PI with a detection reagent.

Claims (13)

1. A method for the measurement of active alpha 1 -proteinase inhibitor (A1PI) in a sample, comprising the steps of

(a) binding elastase to a solid phase, wherein the elastase bound to the solid phase retains its enzymatic activity;

(b) incubating the solid phase from step (a) with the sample; and then washing the solid phase;

(c) incubating the solid phase from step (b) with a detection reagent specifically binding to A1PI, wherein the detection reagent comprises an A1PI epitope binding domain, and then washing the solid phase;

(d) determining the amount of detection reagent bound to the solid phase in step (c); and

(e) thereby determining the amount of active A1PI in the sample.

2. The method according to claim 1 , further comprising the step of blocking the solid phase with bovine serum albumin prior to step (b).

3. The method according to claim 1 , further comprising the step of diluting the sample prior to incubation with the solid phase in step (b).

4. The method according to claim 1 , wherein the elastase is porcine elastase.

5. The method according to claim 1 , wherein the solid phase is a microplate.

6. The method according to claim 1 , wherein the detection reagent is conjugated to peroxidase.

7. The method according to claim 1 , wherein the detection reagent is selected from an antibody, an antibody fragment, a camelized antibody, a camelized antibody fragment, a Fv fragment, a single chain Fv (scFv) fragment, a Fab′fragment, a F(ab′)2 fragment, a chimeric antibody and a multivalent version or a combination thereof.

8. The method according to claim 7 , wherein the detection reagent is conjugated to peroxidase.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036367/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036367/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2012
From: WEBER, ALFRED; ENGELMAIER, ANDREA; SCHWARZ, HANS-PETER
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 028517/0223 →